Dostarlimab is a new type of treatment for women with recurrent or advanced endometrial cancer. The drug was approved for treatment based on the findings of a clinical study called GARNET, originally published in JAMA Oncology. This plain language summary, called ‘Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer’ helps patients and other people affected by endometrial cancer understand the results of the GARNET study.
Read the article in full here.
The original article, entitled ‘Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer. A Nonrandomized Phase 1 Clinical Trial’ published in JAMA Oncology, can be found here.